

Oncologic Applications Of Molecular Coincidence Detection: Its Impact On Patient Management

THESIS

**Submitted for partial fulfillment of
MD Degree in
*Radiotherapy - Nuclear Medicine***



By

Hossam Ahmed Maher El-Zeftawy

(M.B., B.Ch., M.Sc.)

Supervisors

Prof. Dr. Salwa M. Ibrahim, M.D. Prof. Dr. Shawki El-Haddad, M.D.

Professor of Radiation Oncology
and Nuclear Medicine

Professor of Nuclear Medicine,
Ksr El Aini Hospital, Cairo University

Faculty of Medicine, Ain Shams University

Cairo Egypt

Prof. Dr. Hussein M. Abdel-Dayem

Professor of Radiology, Chief of Nuclear Medicine
Saint Vincents Hospital and Medical Center
New York Medical Collage, Valhalla. NY USA

**Faculty of Medicine
Ain Shams University
1999**

ACKNOWLEDGEMENT

I wish to express my sincere appreciation to ***Prof. Dr. Salwa M. Ibrahim***, Professor of Radiation Oncology and Nuclear Medicine, Faculty of Medicine , Ain Shams University, not only for the honor she gave me by supervising this work, but also for her continuous encouragement since my first step in the field. She gave me much of her time, taught me persistence, methods of scientific research, constructive criticism and careful supervision. I owe what is beyond expression for her valuable guidance, enthusiastic cooperation, moral support and sincere scientific advice.

I would like to express my internal indebtedness to ***Prof. Dr. Shawki El-Haddad***, Professor of Nuclear Medicine, Ksr El Aini Hospital, Cairo University, Cairo Egypt, for his guidance, precious encouragement and support.

My deepest gratitude is due to ***Prof. Dr. Hussein M. Abdel-Dayem***, Professor of Radiology, Chief of Nuclear Medicine, Saint Vincents Hospital and Medical Center New York Medical Collage, for his enormous support and fruitful guidance. It was him who suggested the topic and helped me throughout this work patiently and supplied me with a wealth of articles which have expanded my view greatly.

I am most appreciative to all my professors and colleagues of the Radiotherapy and Nuclear Medicine department of Ain Shams University for their cooperation and valuable help.

I will always be grateful to my family for their encouragement, support and tolerance. Their worm feelings and unison cooperation was the backbone of my persistence to accomplish this work.



LIST OF ABBREVIATION

No	Abbreviation	Meaning
1	AIDS	Required Immunodeficiency Syndrome
2	B.Epith.mass	Benign Epithelialmass
3	BSA	Body Surface Area
4	B & ST	Bones and Soft Tissue
5	CA	California
6	Ca	Cancer
7	cc	cubic centimeter
8	C inflam.	Chronic Inflammation
9	CT	Computed Tomography
10	3-D	Three Dimensional
11	2DG	2-Deoxy-D-Glucose
12	FDG	Fluoro-2-deoxy-2-glucose
13	FGS	Female Genital System
14	FN	False Negative
15	FP	False Positive
16	Fu	Follow up
17	Ga-67	Gallium-67 citrate
18	GIT	Gastrointestinal Tract
19	GLUT	Glucose Transporter

19	GLUT	Glucose Transporter
20	H & N	Head & Neck
21	HCC	Hepatocellular Carcinoma
22	hTg	Human Thyroglobulin
23	ICRP	International Committee for Radiation Protection
24	Interst.fibro.	Interstitial Fibrosis
25	$^{131}\text{-I}$	Iodine-131
26	kg	Kilogram
27	kcps	Kilo counts per seconds
28	keV	kilo electron volt
29	Leom.	Leiomyosarcoma
30	LUL	Left Upper Lung Lobe
32	mCi	millicurie
33	MCD	Molecular Coincidence Detection
34	MGS	Male Genital System
35	MRI	Magnetic Resonance Imaging
36	MIBG	Metaiodobenzyl Guanidine
37	Met	L-methyl- ^{14}C -methionine
38	NSCCa	Non Small Cell Lung Carcinoma
39	^{18}O	Oxygen-18

40	PET	Positron Emission Tomography
41	PNET	Primitive Neuro Ectodermal Tumor
42	PVNS	Primitive Villo Nodular Synovial Sarcoma
43	RLL	Right Lower Lung Lobe
44	PUL	Right Upper Lung Lobe
45	SPECT	Single Photon Emission Computed Tomography
46	STS	Soft Tissue Sarcoma
47	SUV	Standard Uptake Value
48	Tc-99m MIBI	Technetium-99m sestamibi (Methoxy isobutyl isonitrile).
49	T/B	Tumor/Background
50	TP	True Positive

* Adding this list is suggested by Prof. Dr. Asmaa Ali Hassan

ERRATA LIST

Page	Default	Correctin
11	(Actolun et al, 1992 and Kao et al, 1993)	(Actalun et al, 1992)
20	m/Ci	mCi
24	Brownnell et al,	Brownnell et al, 1980
24	Reivich et al,	Reivich et al, 1979
24	Jones et al,	Jones et al, 1982
24	IRCP	IRCP 1988
24	Mejia et al,	Mejia et al, 1991
25	In thee cases FDG can provide	sentence repeated
26	A multicenter comp. . table (4)	A multicenter. . is presented in table (4)
29	Pat	Patz
29	Higahsi 1995	Higashi, 1993
62	The 109 study group	The 122 study group
62	Fourth 5 patients with brain	Senstence repeated.
95	FDG PET 9/25/98	T ₁ & T ₂ dorsal vertebrae proved . . . received chemotherapy.
100	Delbeke et al study	Delbeke et al study 1998
103	16-Buchpiguel CA . . 1998	16-Buchipiguel CA . . 1994
106	38-Ginsberg R , . 1993	38-Ginsberg R, . . 1998
106	41-Haberkarn U, . . J Nucl med	41-Haberkorn U, . . J Nucl Med
111	86-Moog F, . . 1999	86-Moog F, . . 1998
112	99-Ottos, Nettelblatt ..	99-Ottos A, . . J Nacl Med 1995; 46: 47 P.
114	119-Schiepers C, . . 1995	119-Schiepers C, .. 1996
116	133-Tonami N, . . 1977	133- Tonami N, . . 1997
116	136-Valk P, .. 1995	136-Valk P, . . 1996
117	145-Warburg O, . . 1991	145- Warburg O, . . 1931

#	Name	Page
1	Introduction	2
2	Aim of the work	4
3	Review of literature	5
	A) Epidemiology and biology of cancer	5
	B) Objectives of imaging cancer patients	6
	C) Limitations of morphologic imaging	7
	D) Drawbacks of non-positron agents	9
	E) Cyclotron produced radiopharmaceuticals	12
	F) 18-F Fluorodeoxy glucose (FDG)	14
	*Chemical composition	14
	*Production	14
	*Mechanism of uptake	15
	*Comparison with non-positron emitting substances	19
	*Quantitation of uptake	20
	*Absorbed dose	22
4	Oncologic applications of PET with FDG	25
5	Coincidence detection Imaging on dual head camera	31
	1- General	31
	2- Camera modification	32
	3- Physical principles for coincidence imaging	35
	* Data acquisition and image reconstruction	36
	* Attenuation correction	36
6	Material and methods	38
	Dose and route of administration	39
	Imaging technique	40
	Image interpretation	43
7	Results	44
8	Discussion	61
	Case presentations	64
9	Summary and conclusion	100
	References	102

List of Tables

Table #	Name	Page
1	Physical characteristics and clinical uses of cyclotron produced products	13
2	Organ uptake of FDG	23
3	radiation absorbed dose in various organs	24
4	Comparison between sensitivity of morphologic and physiologic imaging	29
5	Comparison between morphologic and physiologic imaging in colorectal and B&St sarcoma	30
6	Resolution of tracers with 3/8" and 5/8" crystal thickness	33
7	Comparison between SPECT, DHCI and PET in clinical applications	37
8	Patient group distribution according to primary tumor site of origin	44
9	Pathology results of 109 patients	46
10	FDG results in patients with primary lung cancer	47
11	FDG DHCI results in patients with benign lung lesions	48
12	FDG DHCI results in patients with bone and soft tissue lesions	49
13	FDG DHCI results in postoperative patients with primary bone and soft tissue lesions	50
14	FDG DHCI results in patients with gastrointestinal tumors	51
15	FDG DHCI results in patients with brain and head and neck lesions	51
16	FDG DHCI results in patients with female genital system lesions	52
17	FDG DHCI results in patients with testicular tumors	52
18a&b	Results of FDG DHCI in baseline and follow up studies	53-54
19	Comparison between FDGDHCI and CT/MRI	56
20	Comparison between specificity of FDG DHCI and CT/MRI	57
21	Comparison between positive predictive value of FDG DHCI and CT/MRI	58
22	Comparison between positive predictive value of FDG DHCI and CT/MRI	59
23	Comparison between accuracy of FDG DHCI and CT/MRI	60

List of Figures

Fig Name	Page
1 Chemical composition of FDG	14
2 Comparison between normal and malignant cells in glucose uptake	15
3 Annihilation interaction	31
4 ADAC Vertex Dual Head Gamma camera	42
5 Patient groups according to site of tumors	45
6 Comparison between sensitivity of FDG DHCI and CT/MRI	56
7 Comparison between specificity of FDG DHCI and CT/MRI	57
8 Comparison between positive predictive value of FDG DHCI and CT/MRI	58
9 Comparison between negative predictive value of FDG DHCI and CT/MRI	59
10 Comparison between accuracy of FDG DHCI and CT/MRI	60

I Introduction

I Introduction

The rationale behind using fluorine-18 fluoro -2- deoxy -2- glucose (FDG) positron emission tomography (PET) and dual head coincidence imaging (DHCI) in detection of malignant tumors is to measure and quantify glucose utilization rate in detection of malignant tumors. With increasing malignant transformation, tumor cells regulate up their membrane glucose transporter proteins and increase the enzymes associated with the non-oxidative as well as the oxidative metabolic pathways of glucose. These alterations in neoplastic cells explain the enhanced tumor cell glucose utilization and differential accumulation of FDG in malignant cells more than normal ones (Kahn et al 1990).

Computed tomography (CT) and magnetic resonance imaging (MRI) can determine tumor volume and anatomical location however, both fall short in their ability in many instances to differentiate benign from malignant lesions, detect whether lymph nodes are involved by tumor tissue or not, assess the response to cancer treatment, detect early recurrence and differentiate post-treatment fibrosis and necrosis from malignant recurrence (Sokoloff et al 1998).

Non-positron emitting radiopharmaceuticals such as gallium-67 and thallium-201 that accumulate in viable tumor tissue suffer from their poor emission characteristics and low tumor detection specificity (Matsuno et al 1992). Even tracers with favorable nuclear properties for SPECT imaging such as technetium-99m methoxyisobutyl isonitrile (Tc-99m MIBI) were found to have a low tumor retention index and low tumor to background ratio (Nishiyama et al 1997).

II Aim Of The Work

II Aim Of The Work

We aim to review the results of FDG-DHCI studies performed at our institution, between August 1996 and April 1998, to evaluate the sensitivity, specificity, positive predicative value, negative predictive value and accuracy of this new modality and correlate FDG DHCI results with other imaging modalities (CT/MRI) and pathological examination in order to determine the implication of the DHCI technique in management of cancer patients.

III Review Of Literature